RADHAKISHAN PHARMACEUTICALS
ERLONAT ERLOTINIB TABLETS
ERLONAT ERLOTINIB TABLETS
ERLONAT ERLOTINIB TABLETS

ERLONAT ERLOTINIB TABLETS

MOQ : 100 Boxes

ERLONAT ERLOTINIB TABLETS Specification

  • Dosage Form
  • Tablets
  • Salt Composition
  • Erlotinib Hydrochloride
  • Origin
  • India
  • Indication
  • Non-Small Cell Lung Cancer, Pancreatic Cancer
  • Feature
  • Other
  • Ingredients
  • Other
  • Application
  • Anticancer Medication
  • Physical Color/Texture
  • White to off-white tablets
  • Fermentation Smell
  • Odorless
  • Storage Instructions
  • Cool & Dry Place
  • Shelf Life
  • 36 Months
  • Packaging Size
  • 30 Tablets per box
  • Marketed By
  • Natco Pharma Ltd.
  • Packaging Type
  • Blister Strip
  • Route of Administration
  • Oral
  • Prescription Required
  • Yes
  • Strength
  • 100 mg / 150 mg
 

ERLONAT ERLOTINIB TABLETS Trade Information

  • Minimum Order Quantity
  • 100 Boxes
  • Supply Ability
  • 1000 Boxes Per Week
  • Delivery Time
  • 1 Days
  • Packaging Details
  • PACK OF 30 TABLETS
  • Main Domestic Market
  • All India
 

About ERLONAT ERLOTINIB TABLETS

Erlonat Tablets

Erlonat contains erlotinib and belongs to a class of medications called kinase inhibitors. Erlonat is used for the treatment of non-small cell lung cancer. Erlonat is used in combination with gemcitabine for the treatment of pancreatic cancer that has spread to nearby tissues or to other parts of the body. The Erlotinib hydrochloride Tablets offered by us are also known as Erlonat...

Available as: 25 mg, 100 mg & 150 mg Tablets

Manufactured By: NATCO

Technical specification

  • Product Name:Erlonat
  • Contains:Erlotinib hydrochloride
  • Form:Tablet
  • Strength:25 mg, 100 mg & 150 mg
  • Packing:Pack Of 30 Tablets


NOTE :- Erlonat is a prescription drug and should be used under proper medical guidance and advice. Do not share the medicine with others, since they may be suffering from a problem that is not effectively treated by this drug...........



Benefits of ERLONAT Erlotinib Tablets

ERLONAT provides targeted therapy for non-small cell lung cancer and pancreatic cancer. Its oral formulation makes administration convenient for patients, and the medication is recognized for its efficacy in managing advanced stages of these cancers by inhibiting specific cancer cell growth pathways. The blister strip packaging maintains the integrity of each tablet.


Proper Usage and Dosage Measures

ERLONAT tablets should be taken orally as directed by a qualified healthcare professional. Dosage strength is available in 100 mg and 150 mg options and should be determined based on individual medical assessment. It is crucial to follow prescription guidelines and not self-adjust dosage without medical consultation to ensure treatment safety and efficacy.


Packaging and Storage Recommendations

Supplied in blister strips within boxes containing 30 tablets each, ERLONATs packaging protects the product from moisture and contamination. Store the tablets in a cool, dry environment and ensure they are kept out of reach of children. Proper storage is vital to maintaining potency throughout the 36-month shelf life.

FAQs of ERLONAT ERLOTINIB TABLETS:


Q: How should ERLONAT Erlotinib Tablets be taken for maximum effectiveness?

A: The tablets should be administered orally exactly as prescribed by a healthcare provider, typically once daily. It is advisable to take them on an empty stomach, at least one hour before or two hours after a meal, unless otherwise instructed by your doctor.

Q: What is the primary indication for ERLONAT Erlotinib Tablets?

A: ERLONAT is primarily indicated for the treatment of non-small cell lung cancer and pancreatic cancer, usually in cases where the disease is advanced or metastatic.

Q: When is a valid prescription required to obtain ERLONAT Erlotinib Tablets?

A: A valid medical prescription is required at all times to purchase ERLONAT, as it is a regulated anticancer medication intended only for patients under professional medical supervision.

Q: Where is ERLONAT Erlotinib Tablets manufactured and distributed?

A: ERLONAT tablets are manufactured and marketed by Natco Pharma Ltd. in India and distributed by authorized exporters, suppliers, traders, and wholesalers throughout the country and internationally.

Q: What are the packaging specifications of ERLONAT Erlotinib Tablets?

A: Each box contains 30 tablets packed in blister strips, which help preserve the tablets quality and prevent exposure to environmental contaminants. The tablets are white to off-white and odorless.

Q: How should ERLONAT Erlotinib Tablets be stored to maintain their quality?

A: Store ERLONAT tablets in a cool, dry place away from direct sunlight and moisture. Proper storage extends the shelf life to 36 months and protects the medications efficacy.

Q: What benefits can patients expect from taking ERLONAT Erlotinib Tablets?

A: Patients can benefit from ERLONATs targeted action against cancer cell growth in non-small cell lung cancer and pancreatic cancer, potentially improving disease management and quality of life.

Tell us about your requirement
product

Price:

Quantity
Select Unit

  • 50
  • 100
  • 200
  • 250
  • 500
  • 1000+
Additional detail
Mobile number

Email

More Products in Anticancer Medicines Category

ERLOCIP ERLOTINIB TABLETS IP

ERLOCIP ERLOTINIB TABLETS IP

Salt Composition : Erlotinib Hydrochloride (equivalent to Erlotinib) 150 mg

Shelf Life : 24 months

Dosage Form : Filmcoated Tablet

Application : Other, Anticancer Therapy

Ingredients : Other , Erlotinib Hydrochloride, Excipients

Feature : Other, Oral Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor

VEENAT IMATINIB 100MG CAPSULES

VEENAT IMATINIB 100MG CAPSULES

Salt Composition : Imatinib Mesylate 100mg

Shelf Life : 24 months from the date of manufacture

Dosage Form : Capsules

Application : Other, Oral chemotherapy, prescription only

Ingredients : Other , Imatinib Mesylate and excipients

Feature : Other, Targeted therapy for certain cancers, trusted brand, convenient oral dosage

MYEZOM BORTEZOMIB 3.5 MG INJECTION

MYEZOM BORTEZOMIB 3.5 MG INJECTION

Salt Composition : Bortezomib 3.5 mg

Shelf Life : 24 months

Dosage Form : Injection

Application : Other, Cancer treatment

Ingredients : Other , Bortezomib

Feature : Other, Antineoplastic agent; administered intravenously or subcutaneously

VORIZOL VORICONAZOLE INJECTION

VORIZOL VORICONAZOLE INJECTION

Salt Composition : Voriconazole 200 mg/vial

Shelf Life : 24 months

Dosage Form : Injection

Application : Other, Intravenous use for patients unable to take oral medication

Ingredients : Other , Voriconazole, excipients (including solubilizing agents and stabilizers)

Feature : Other, Broadspectrum antifungal, lyophilized for intravenous use



Back to top